It doesn’t hurt to stop XELOX chemotherapy combined with Avastin after six treatments and continue with Avastin alone until colorectal cancer gets worse, according to a study reported at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

Many patients have to stop oxaliplatin chemotherapy with before getting its maximum effectiveness because of peripheral neuropathy — tingling, numbness, or pain in their hands and feet.  Xeloda® (capecitabine) can cause painful skin redness and cracking on the hands and feet or hand-foot syndrome, which can also affect time on chemotherapy.

Giving only six treatments of Avastin® (bevacizumab) plus XELOX chemotherapy and then stopping XELOX and using only Avastin until cancer progressed was as effective for the initial or first-line treatment of colorectal cancer as continuing XELOX.  XELOX combines Xeloda® (capecitabine) with oxaliplatin.

In addition, the strategy reduced both severe peripheral neuropathy and hand-foot syndrome.

Read the rest of this entry »

Colorectal cancer patients benefited when they continued to include Avastin® (bevacizumab) in their chemotherapy plan after their cancer got worse after initial treatment.

They lived longer after beginning a second round of chemotherapy with Avastin than did other patients who got chemo without Avastin or those who didn’t get any chemotherapy at all.

The results are based on the ARIES study which observed patients after cancer progressed after either first or second line chemotherapy with Avastin.  The analysis will be presented at the American Society of Clinical Oncology in June. Read the rest of this entry »

Briefly:

A video can help patients make personal decisions about end-of-life care.  Cancer death rates are falling in Europe, partly led by recent colorectal cancer declines.

Avastin will now be covered for a longer time for people with advanced colorectal cancer in Ontario.  The Wellness Community in Valley/Ventura, California has a free workshop scheduled for December 19th featuring Dr. Heinz-Josef Lenz. Read the rest of this entry »

Colorectal cancer patients 65 and older without other serious medical problems benefitted when Avastin® (bevacizumab) was added to chemotherapy.

Combining results of four randomized clinical trials of Avastin and chemotherapy in patients with advanced colorectal cancer, researchers found that adding Avastin increased both the time older patients lived and the time before their cancer got worse.

Patients who were 70 and older had similar improvements. Read the rest of this entry »

Get help managing the financial costs of your cancer care from an ASCO booklet or figure out how to deal with the Medicare prescription doughnut hole using an AARP online calculator.

In research, Lynch syndrome women have excellent survival after ovarian cancer, older patients have similar effectiveness and side effects from Avastin, and parents with advanced cancer often underestimate how upset their children are.  Long-term cancer survivors have no more depression than people without cancer. Read the rest of this entry »